Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 730.08 M
The data is delayed by 15 minutes.
Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was found
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||15.64 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||526.88%||Sales Growth - Q/Q||548.38%||P/E|
|P/E To EPS Growth||P/S||14.45||P/BV||7.1||Price/Cash Per Share|
|Price/Free Cash Flow||-52.57||ROA||1.66%||ROE||2.09%||ROI|
|Current Ratio||4.8||Quick Ratio||4.72||Long Term Debt/Equity||Debt Ratio||0.26|
|Gross Margin||71.95%||Operating Margin||2.84%||Net Profit Margin||4.26%||Dividend Payout Ratio|
|Cash From Financing Activities||55.29 M||Cash From Investing Activities||3.95 M||Cash From Operating Activities||17.96 M||Gross Profit||30.36 M|
|Net Profit||19.7 M||Operating Profit||20.09 M||Total Assets||129.93 M||Total Current Assets||129.79 M|
|Total Current Liabilities||27.05 M||Total Debt||Total Liabilities||27.05 M||Total Revenue||36.31 M|
|High 52 week||67.49||Low 52 week||36.72||Last close||61.99||Last change||2.07%|
|RSI||86.41||Average true range||1.81||Beta||1.24||Volume||253.51 K|
|Simple moving average 20 days||6.76%||Simple moving average 50 days||7.94%||Simple moving average 200 days||20.46%|
|Performance Week||5.28%||Performance Month||5.5%||Performance Quart||13.89%||Performance Half||23.98%|
|Performance Year||3.08%||Performance Year-to-date||53.86%||Volatility daily||1.68%||Volatility weekly||3.75%|
|Volatility monthly||7.68%||Volatility yearly||26.62%||Relative Volume||311.49%||Average Volume||149.42 K|
|New High||New Low|
2019-11-20 06:50:00 | Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference
2019-11-18 21:32:30 | Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT
2019-11-12 08:15:01 | Eagle Pharmaceuticals EGRX Q3 Earnings and Revenues Lag Estimates
2019-11-12 06:51:00 | Eagle Pharmaceuticals Reports Third Quarter 2019 Results
2019-11-09 14:26:20 | Do Hedge Funds Love Eagle Pharmaceuticals Inc EGRX?
2019-10-17 09:28:01 | New Strong Sell Stocks for October 17th
2019-10-02 14:39:07 | Here's What Eagle Pharmaceuticals, Inc.'s NASDAQ:EGRX P/E Is Telling Us
2019-09-23 16:30:00 | Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference
2019-09-23 08:32:12 | 5 Momentum Picks Screened on Driehaus Strategy
2019-09-10 07:29:32 | Does The Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Share Price Tend To Follow The Market?
2019-09-04 08:40:12 | Insulet PODD Catches Eye: Stock Jumps 8.9%
2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta
2019-08-18 10:21:44 | Should Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Be Your Next Stock Pick?
2019-08-14 10:29:02 | New Strong Buy Stocks for August 14th
2019-08-11 12:29:42 | Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT
2019-08-09 06:23:49 | Eagle Pharmaceuticals Inc EGRX Q2 2019 Earnings Call Transcript
2019-08-08 08:45:12 | Eagle Pharmaceuticals EGRX Beats Q2 Earnings and Revenue Estimates
2019-08-08 06:50:00 | Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results
2019-08-05 06:50:00 | Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor ER-Positive Breast Cancer
2019-08-01 10:33:02 | Earnings Preview: Eagle Pharmaceuticals EGRX Q2 Earnings Expected to Decline
2019-07-29 16:30:00 | Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019
2019-07-26 07:54:59 | Is Eagle Pharmaceuticals NASDAQ:EGRX Using Too Much Debt?
2019-07-03 13:59:00 | Should You Worry About Eagle Pharmaceuticals, Inc.'s NASDAQ:EGRX CEO Pay Cheque?
2019-06-15 08:05:07 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-06-13 08:02:18 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-06-11 08:02:57 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-06-10 08:05:21 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-06-06 08:05:01 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-06-04 08:05:13 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-05-31 15:07:47 | Here's Why I Think Eagle Pharmaceuticals NASDAQ:EGRX Might Deserve Your Attention Today
2019-05-28 16:30:00 | Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
2019-05-09 20:43:25 | Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc EGRX
2019-05-08 06:00:00 | Can Eagle Pharma Fly through its Oncology Trials
2019-05-07 17:50:27 | Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT
2019-05-07 12:23:21 | Eagle Pharmaceuticals Inc EGRX Q1 2019 Earnings Call Transcript
2019-05-07 08:05:12 | Eagle Pharmaceuticals EGRX Beats Q1 Earnings and Revenue Estimates
2019-05-07 08:04:35 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
2019-05-07 07:04:52 | Did You Miss Eagle Pharmaceuticals's NASDAQ:EGRX Whopping 457% Share Price Gain?
2019-05-07 06:58:29 | Eagle Pharmaceuticals: 1Q Earnings Snapshot